en · de · es · fr · pt
selank-notes.peptides1126.com › Guide › Selank Background And Peptide Chemistry — Practical Notes

Selank Background And Peptide Chemistry — Practical Notes

By Editorial Desk · published 2026-04-29 · last reviewed 2026-05-20 · Guide

A practical reference on peptidase: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-05-20. Anything still debated is marked as such rather than presented as settled.

Selank Background and Peptide Chemistry

Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.

Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.

Analytical Methods and Stability

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.

Selank at a glance

PropertyValueNotes
Molecular formulaC33H57N11O9Derived from the seven-residue sequence
Molecular weightAbout 751.9 g/molAverage mass; the monoisotopic value is slightly lower
Residue countSeven amino acidsThr-Lys-Pro-Arg-Pro-Gly-Pro
Parent compoundTuftsin (Thr-Lys-Pro-Arg)Selank extends tuftsin at the C-terminus
Compound classSynthetic short peptideStudied in a research setting; not a licensed drug in most markets

Mechanism and Evidence Status

Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.

Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.

Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.

Related pages on this site

Mechanism and Evidence Base

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Background and Molecular Identity

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Peptide Identity and Structure

Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.

Notes from published material

=== Drawing paste === In the United Kingdom, a medication containing magnesium sulfate, called "drawing paste", is claimed to be useful for small boils or localised infections, and removing splinters. The standard British Pharmacopoeia composition is dried magnesium sulfate 47.76% (by mass), phenol 0.49%, and glycerol to balance.

=== Welsh === Llanfair­pwllgwyngyll­gogery­chwyrn­drobwll­llan­tysilio­gogo­goch, a railway station on the island of Anglesey in Wales, is the longest place name in the Welsh language. At 51 letters in the Welsh alphabet (the digraphs ll and ch are each collated as single letters) the name can be translated as "St Mary's church in the hollow of the white hazel near to the rapid whirlpool and the church of St Tysilio of the red cave". However, it was artificially contrived in the 1860s as a publicity stunt, to give the station the longest name of any railway station in the United Kingdom. Long words are comparatively rare in Welsh. Candidates for long words other than proper nouns include the following (the digraph dd is also treated as a single letter, as is ng in many instances including in the last word below):

In biology, organs are defined as confined functional units within an organism. The analogy of bodily organs to microscopic cellular substructures is obvious, as from even early works, authors of respective textbooks rarely elaborate on the distinction between the two. In the 1830s, Félix Dujardin refuted Ehrenberg's theory that microorganisms have the same organs as multicellular animals, only smaller. Credited as the first to use a diminutive of organ (i.e., little organ) for cellular structures was German zoologist Karl August Möbius (1884), who used the term organula (plural of organulum, the diminutive of Latin organum). In a footnote, which was published as a correction in the next issue of the journal, he justified his suggestion to call organs of unicellular organisms "organella" since they are only differently formed parts of one cell, in contrast to multicellular organs of multicellular organisms.

Tolerance to psilocybin appears after a single dose and dissipates dissipates after a few days. A cross-tolerance can develop between psilocybin and other classical psychedelics such as LSD, mescaline and DOM. Repeated use of psilocybin does not lead to physical dependence or drug withdrawal. Despite the rapid onset of tolerance, rates of self-administration in Rhesus macaques are low, which usually indicates a low abuse potential. A 2008 study concluded that, based on U.S. data from 2000 to 2002, adolescent-onset usage of hallucinogenic drugsdid not increase the risk of drug dependence in adulthood; this was in contrast to adolescent usage of cannabis, cocaine, inhalants, anxiolytic medicines, and stimulants, all of which were associated with "an excess risk of developing clinical features associated with drug dependence". Multiple studies in 2010 ranked the relative harm of psilocybin mushrooms below all other drugs in a selection of 19 recreational drugs, including alcohol, cannabis, cocaine, ecstasy, heroin, and tobacco.

== Research limitations and scientific uncertainty == Despite growing concern and evidence, most epidemiologic studies have focused on characterizing exposures rather than direct health impacts. Epidemiological studies directly linking MNPs to adverse health effects in humans still remain relatively limited and research is ongoing to determine the full extent of potential harm caused by MNPs and their long-term impact on human health. Public health agencies have acknowledged that there is a need for further research on assessing exposure levels and possible public health implications. Ongoing research aims to clarify exposure pathways, biological interactions, and risks. A major limitation involves the lack of standardized methods for detecting and quantifying nanoplastics in environmental and biological samples. Variability in sampling techniques influences inconsistent data records. Accurately measuring nanoplastics is technically challenging because of their small size and different properties. For example, there is risk of sample contamination during collection, differences in whether studies report particle counts versus mass concentrations, and difficulty differentiating the effects of microplastics from the effects off absorbed pollutants. Additionally, much of the existing evidence originates from laboratory experiments and animal models, which may not directly reflect human exposure. Differences in particle size, shape, and chemical additives also complicate comparisons across studies.

Sources: en.wikipedia.org

Further detail

perlatum's physiological responses are significantly influenced by water availability. The ability to maintain higher photosynthetic performance and pigment content in humid conditions suggests that P. perlatum is better adapted to environments with higher moisture levels. This adaptability makes P. perlatum useful as a bioindicator for monitoring ecological responses to climate change and varying moisture conditions in Mediterranean ecosystems. Lichenicolous (lichen-dwelling) fungi that have been recorded parasitising Parmotrema perlatum include Abrothallus parmotrematis, Briancoppinsia cytospora, Lichenoconium erodens, and Spirographa lichenicola.

=== Courier services === There are a large number of local and international courier companies operating in South Africa, delivering documents and parcels on-demand for individuals and commercial entities. These companies provide services such as domestic and international delivery, cross-border e-commerce logistics, customs clearance, freight forwarding, warehousing, distribution, and last-mile parcel delivery. Courier companies operating in SA include:

=== Foreign policy === Gallrein supported the 2026 U.S. intervention in Venezuela. Commenting on the 2026 Iran War, Gallrein said on X on February 28, 2026, that the United States' attack on Iran: "sends a clear message to the world: The United States will not sit back while a hostile regime continually threatens our Nation, our allies, and global stability as Iran has for decades as the leading state sponsor of terrorism been responsible for the death of U.S. citizens and servicemembers.... Decisive action, clear objectives, and overwhelming strength save American lives and prevent larger wars, death, and destruction."

=== Factors other than glucose that affect A1c === Lower-than-expected levels of HbA1c can be seen in people with shortened red blood cell lifespans, such as with glucose-6-phosphate dehydrogenase deficiency, sickle-cell disease, or any other condition causing premature red blood cell death. Other variant hemoglobins, such as HbF or HbE, may have different glycation characteristics or respond differently in a HbA1c test. For these patients, alternate assessment with fructosamine or glycated albumin is recommended; these methods reflect glycemic control over the preceding 2–3 weeks. In a blood donor, donation will result in loss of mature RBCs and their rapid replacement with newly formed red blood cells. Since these new RBCs will have only existed for a short period of time, their presence will lead HbA1c to underestimate the actual average levels. There may also be distortions resulting from blood donation during the preceding two months, due to an abnormal synchronization of the age of the RBCs, resulting in an older than normal average blood cell life (resulting in an overestimate of actual average blood glucose levels). Conversely, higher-than-expected levels can be seen in people with a longer red blood cell lifespan, such as with iron deficiency. Results can be unreliable in many circumstances, for example after blood loss, after surgery, blood transfusions, anemia, or high erythrocyte turnover; in the presence of chronic renal or liver disease; after administration of high-dose vitamin C; or erythropoetin treatment. Hypothyroidism can artificially raise the A1c.

==== Radical site-initiated fragmentation ==== Sigma bond cleavage also occurs on radical cations remote from the site of ionization. This is commonly observed in alcohols, ethers, ketones, esters, amines, alkenes, and aromatic compounds with a carbon attached to ring. The cation has a radical on a heteroatom or an unsaturated functional group. The driving force of fragmentation is the strong tendency of the radical ion for electron pairing. Cleavage occurs when the radical and an odd electron from the bonds adjacent to the radical migrate to form a bond between the alpha carbon and either the heteroatom or the unsaturated functional group. The sigma bond breaks; hence this cleavage is also known as homolytic bond cleavage or α-cleavage.

Sources: en.wikipedia.org

Frequently asked questions

What is selank?

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.

How does selank differ from tuftsin?

Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.

Is the mechanism of action established?

No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.

How is selank identified in a laboratory?

Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.

Network